KHPG(SZ:002773) Ge Long Hui A P P·2025-09-29 10:58Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) is enhancing its gene therapy development by increasing capital in its subsidiary, Chengdu Hongji Biotechnology Co., Ltd. (referred to as "Hongji Bio") to support strategic planning and motivate management teams [1] Group 1: Capital Increase Details - The capital increase amount is 1.54 million yuan, with contributions from three management consulting partnerships: Kangji contributing 460,000 yuan, Kangyin contributing 370,000 yuan, and Kangzhi contributing 710,000 yuan [1] - The company has waived its preferential subscription rights for this capital increase [1] Group 2: Corporate Structure Changes - Hongji Bio has completed the registration of increased capital and changes in shareholding structure, obtaining a new business license from the Chengdu Market Supervision Administration [1] - The company's shareholding in Hongji Bio has decreased from 86.95% to 86.53%, but Hongji Bio remains a controlled subsidiary and is included in the company's consolidated financial statements [1]